Search clinical trials for: ceralasertib

Total 25 results

IFOM ETS - The AIRC Institute of Molecular Oncology
AstraZeneca

Recruiting

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel (ATRiBRAVE)

Triple Negative Breast Cancer Metastatic

Italy
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Clinical Stage... and other conditions

United States
Muhammad Furqan
AstraZeneca

Recruiting

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

United States
University of Leeds
University College London Hospitals; The Leeds Teaching Hospitals NHS Trust; University... and other collaborators

Recruiting

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)

Non Small Cell Lung Cancer

United Kingdom
Dana-Farber Cancer Institute
AstraZeneca; Osteosarcoma Institute

Recruiting

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Osteosarcoma | Osteosarcoma Recurrent

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Recruiting

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Rahul Aggarwal
AstraZeneca

Recruiting

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Endometrial Cancer | Stage III Renal Cell Cancer | Locally Advanced Malignant Solid Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IV... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Recruiting

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)

Pediatric Cancer

Italy, France, Denmark, Germany, Netherlands, Spain, United Kingdom
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
AstraZeneca
Parexel

Active, not recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
AstraZeneca

Active, not recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

Advanced Solid Tumours

China
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy (LOTOS)

Advanced or Metastatic NSCLC

Russian Federation
National Cancer Institute (NCI)

Suspended

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Refractory Cholangiocarcinoma

United States
Assistance Publique Hopitaux De Marseille

Active, not recruiting

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)

Non-small Cell Lung Cancer

France
AstraZeneca

Active, not recruiting

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Non-Small Cell Lung Cancer

France, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
AstraZeneca

Active, not recruiting

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Active, not recruiting

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Metastatic Triple Negative Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
AstraZeneca

Active, not recruiting

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE)

Melanoma

France, Germany, Italy, Spain, Belgium, Canada, Poland, Korea, Republic of, United Kingdom, United States, Australia
AstraZeneca

Active, not recruiting

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Advanced Solid Tumours

United States, France, Spain
University of Michigan Rogel Cancer Center

Active, not recruiting

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Prostate Cancer

United States
AstraZeneca

Completed

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Head and Neck Squamous Cell Carcinoma

Taiwan, United States, France
AstraZeneca
Parexel

Withdrawn

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (DUETTE)

Ovarian Cancer

United States, Italy, Canada, Spain

Search clinical trials for: ceralasertib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations